These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27260022)

  • 1. The EMPA-REG outcome study: critical appraisal and potential clinical implications.
    Perseghin G; Solini A
    Cardiovasc Diabetol; 2016 Jun; 15():85. PubMed ID: 27260022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics.
    Scheen AJ
    Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
    Wanner C; Inzucchi SE; Lachin JM; Fitchett D; von Eynatten M; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; Zinman B;
    N Engl J Med; 2016 Jul; 375(4):323-34. PubMed ID: 27299675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.
    Mudaliar S; Alloju S; Henry RR
    Diabetes Care; 2016 Jul; 39(7):1115-22. PubMed ID: 27289124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
    Ferrannini E; Mark M; Mayoux E
    Diabetes Care; 2016 Jul; 39(7):1108-14. PubMed ID: 27289126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
    Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
    Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    Marso SP; Daniels GH; Brown-Frandsen K; Kristensen P; Mann JF; Nauck MA; Nissen SE; Pocock S; Poulter NR; Ravn LS; Steinberg WM; Stockner M; Zinman B; Bergenstal RM; Buse JB; ;
    N Engl J Med; 2016 Jul; 375(4):311-22. PubMed ID: 27295427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.
    Yoon KH; Nishimura R; Lee J; Crowe S; Salsali A; Hach T; Woerle HJ
    Diabetes Obes Metab; 2016 Oct; 18(10):1045-9. PubMed ID: 27265507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.
    Levine MJ
    Curr Diabetes Rev; 2017; 13(4):405-423. PubMed ID: 27296042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of anti-diabetes drugs.
    Younk LM; Lamos EM; Davis SN
    Expert Opin Drug Saf; 2016 Sep; 15(9):1239-57. PubMed ID: 27268470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibitors in the management of type 2 diabetes.
    Monica Reddy RP; Inzucchi SE
    Endocrine; 2016 Aug; 53(2):364-72. PubMed ID: 27270407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
    White WB; Kupfer S; Zannad F; Mehta CR; Wilson CA; Lei L; Bakris GL; Nissen SE; Cushman WC; Heller SR; Bergenstal RM; Fleck PR; Cannon CP;
    Diabetes Care; 2016 Jul; 39(7):1267-73. PubMed ID: 27289121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.
    Fioretto P; Stefansson BV; Johnsson E; Cain VA; Sjöström CD
    Diabetologia; 2016 Sep; 59(9):2036-9. PubMed ID: 27306615
    [No Abstract]   [Full Text] [Related]  

  • 14. PROTECTIVE EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON PROGRESSION OF DIABETIC RETINOPATHY IN PATIENTS WITH TYPE 2 DIABETES.
    Chung YR; Park SW; Kim JW; Kim JH; Lee K
    Retina; 2016 Dec; 36(12):2357-2363. PubMed ID: 27285457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records.
    Kolaczynski WM; Hankins M; Ong SH; Richter H; Clemens A; Toussi M
    Diabetes Ther; 2016 Sep; 7(3):483-96. PubMed ID: 27262995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of the Key Clinical Trials of 2015: Results and Implications.
    McCune C; McKavanagh P; Menown IB
    Cardiol Ther; 2016 Dec; 5(2):109-132. PubMed ID: 27277596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Options for empagliflozin in combination therapy in type 2 diabetes mellitus.
    Hershon KS
    Int J Gen Med; 2016; 9():155-72. PubMed ID: 27307761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcopenia in Elderly Diabetic Patients: Role of Dipeptidyl Peptidase 4 Inhibitors.
    Rizzo MR; Barbieri M; Fava I; Desiderio M; Coppola C; Marfella R; Paolisso G
    J Am Med Dir Assoc; 2016 Oct; 17(10):896-901. PubMed ID: 27262494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus.
    Koyanagawa N; Miyoshi H; Ono K; Nakamura A; Cho KY; Yamamoto K; Takano Y; Dan-Noura M; Atsumi T
    Endocr J; 2016 Aug; 63(8):747-53. PubMed ID: 27321385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes.
    Baron KT; Macha S; Broedl UC; Nock V; Retlich S; Riggs M
    Diabetes Ther; 2016 Sep; 7(3):455-71. PubMed ID: 27312794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.